M
Mario A. Henriquez
Researcher at Michigan State University
Publications - 11
Citations - 857
Mario A. Henriquez is an academic researcher from Michigan State University. The author has contributed to research in topics: Renal function & Amlodipine. The author has an hindex of 7, co-authored 11 publications receiving 827 citations.
Papers
More filters
Journal ArticleDOI
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Mahboob Rahman,Sara L. Pressel,Barry R. Davis,Chuke Nwachuku,Jackson T. Wright,Paul K. Whelton,Joshua I. Barzilay,Vecihi Batuman,John H. Eckfeldt,Michael A. Farber,Mario A. Henriquez,Nelson Kopyt,Gail T. Louis,Mohammad G. Saklayen,Carol Stanford,Candace Walworth,Harry Ward,Thomas B. Wiegmann +17 more
TL;DR: In hypertensive patients with reduced GFR, neither amlodipine nor lisinopril was superior to chlorthalidone in reducing the rate of development of ESRD or a 50% or greater decrement in GFR.
Journal ArticleDOI
Cardiovascular Outcomes in High-Risk Hypertensive Patients Stratified by Baseline Glomerular Filtration Rate
Mahboob Rahman,Sara L. Pressel,Barry R. Davis,Chuke Nwachuku,Jackson T. Wright,Paul K. Whelton,Joshua I. Barzilay,Vecihi Batuman,John H. Eckfeldt,Michael A. Farber,Stanley S. Franklin,Mario A. Henriquez,Nelson Kopyt,Gail T. Louis,Mohammad G. Saklayen,Carole Stanford,Candace Walworth,Harry Ward,Thomas B. Wiegmann +18 more
TL;DR: It was found that coronary heart disease was much more common than end-stage renal disease in hypertensive patients with moderate to severe reductions in GFR who were followed for 6 years, and lower baseline GFR was associated with higher risk for CHD independent of other risk factors.
Journal ArticleDOI
Progression of Kidney Disease in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin Versus Usual Care: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Mahboob Rahman,Charles Baimbridge,Barry R. Davis,Joshua I. Barzilay,Jan Basile,Mario A. Henriquez,Anne M. Huml,Nelson Kopyt,Gail T. Louis,Sara L. Pressel,Clive Rosendorff,Clive Rosendorff,Sithiporn Sastrasinh,C. Stanford +13 more
TL;DR: In hypertensive patients with moderate dyslipidemia and decreased eGFR, pravastatin was not superior to usual care in preventing clinical renal outcomes, however, benefit from statin therapy may depend on the degree of the cholesterol level decrease achieved.
Journal ArticleDOI
Long-Term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFR
Mahboob Rahman,Charles E. Ford,Jeffrey A. Cutler,Barry R. Davis,Linda B. Piller,Paul K. Whelton,Jackson T. Wright,Joshua I. Barzilay,Clinton D. Brown,Pedro J. Colon,Lawrence J. Fine,Richard H. Grimm,Alok Gupta,Charles Baimbridge,L. Julian Haywood,Mario A. Henriquez,Ekambaram Ilamaythi,Suzanne Oparil,Richard A. Preston +18 more
TL;DR: By eGFR stratum, 5-year treatment with amlodipine or lisinopril was not superior to chlorthalidone in preventing cardiovascular events, mortality, or ESRD during 9-year follow-up, and CKD is associated with significantly higher long-term risk of cardiovascular events and mortality in older hypertensive patients.
Journal ArticleDOI
Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Mahboob Rahman,Sara L. Pressel,Barry R. Davis,Chuke Nwachuku,Jackson T. Wright,Paul K. Whelton,Joshua I. Barzilay,Vecihi Batuman,John H. Eckfeldt,Michael A. Farber,Mario A. Henriquez,Nelson Kopyt,Gail T. Louis,Mohammad G. Saklayen,Carol Stanford,Candace Walworth,Harry Ward,Thomas B. Wiegmann +17 more
TL;DR: In hypertensive patients with reduced GFR, neither amlodipine nor lisinopril was superior to chlorthalidone in reducing the rate of development of ESRD or a 50% or greater decrement in GFR.